C19-9 | non-RGD integrin αvß3 receptor inhibitor

CAS:
 1477482-47-5
Catalog Number:
 10-3977

Available Options

Size:PriceQuantity 
5 mg$50.00
25 mg$150.00

C19-9 (1477482-47-5) is a novel non-RGD inhibitor of the integrin αvß3 receptor (KD = 102 nM).  It was active against the human prostate carcinoma epithelial cell line 22RV1 (IC50 = 467 nM) and human prostate cancer organoids (IC50 = 652 nM).  C19-9 was active in vivo in 22RV1 mouse xenografts and blocked growth in enzalutamide-resistant mouse CRPC xenografts.

References/Citations:

  1. Pang et al. (2023), Discovery of C19-9 as a novel non-RGD inhibitor of αvß3 to overcome enzalutamide resistance in castration-resistant prostate cancer; Signal Transduct. Target Ther. 8 60
CAS:
1477482-47-5
Catalog Number:
10-3977
Activity:
non-RGD inhibitor of the integrin αvß3 receptor
Chemical Names:
N-[(E)-(3-Hydroxy-4-methoxyphenyl)methylideneamino]-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (E)-N’-(3-Hydroxy-4-methoxybenzylidene)-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide
Molecular Weight:
314.35
Molecular Formula:

C16H18N4O3

Solubility:
Soluble in DMSO (at least 50 mg/ml)
Physical Properties:
White to off-white solid
Purity:

>98% by TLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

N/A

Product Data Sheet:

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

20% OFF

For Postdoc
Customers!